Comparative Study Between Levobupivacaine and Bupivacaine for Nerve Block During Pediatric Primary Cleft Palate Surgery
Primary Purpose
Recovery After Cleft Palate Surgery
Status
Completed
Phase
Phase 2
Locations
Egypt
Study Type
Interventional
Intervention
Levobupivacaine
Bupivacaine
Sponsored by
About this trial
This is an interventional prevention trial for Recovery After Cleft Palate Surgery focused on measuring Levobupivacaine, Bupivacaine, Nerve Block, Cleft Palate
Eligibility Criteria
Inclusion Criteria:
- Age 1-10 years
- Both sexes
- ASA I or II
- Primary cleft palate
Exclusion Criteria:
- Any allergy to local anesthetics
- Coagulation disorders
- Local infection or injury at site of MNB
- Concomitant rhinoplasty
- Associated other congenital anomalies
- History of upper or lower airway diseases
- History of sleep apnea
Sites / Locations
- Assiut university hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Group L
Group B
Arm Description
Children will receive 0.15 ml/kg of 0.2% Levobupivacaine
Children will receive 0.15 ml/kg of 0.2% Bupivacaine
Outcomes
Primary Outcome Measures
recovery after surgery
sedation of the child in the recovery room will be monitored
Secondary Outcome Measures
FLACC score
Nalbuphine will be given when visual analogue score ≥ 3
Intraoperative and Postoperative Complications
percentage of patients with any complications will be recorded
Full Information
NCT ID
NCT02923869
First Posted
September 30, 2016
Last Updated
September 5, 2017
Sponsor
Assiut University
1. Study Identification
Unique Protocol Identification Number
NCT02923869
Brief Title
Comparative Study Between Levobupivacaine and Bupivacaine for Nerve Block During Pediatric Primary Cleft Palate Surgery
Official Title
Comparative Study Between Levobupivacaine and Bupivacaine for Nerve Block During Pediatric Primary Cleft Palate Surgery
Study Type
Interventional
2. Study Status
Record Verification Date
September 2017
Overall Recruitment Status
Completed
Study Start Date
January 2016 (Actual)
Primary Completion Date
October 2016 (Actual)
Study Completion Date
October 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Assiut University
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
A cleft deformity of the lip and/or palate is one of the commonest major birth defects.
Primary surgery of cleft palates (CP) varies according to the different surgical teams. Its peculiarity lies in the numerous care management protocols proposed according to the surgical techniques used, operating time (between M3 and M18 of life), anesthetic technique and postoperative management.
This surgery must be associated to a specific care management because of potential associated complications, especially the risk of obstruction of the upper respiratory tract and respiratory distress majored by the use of morphine anesthetics during and after surgery.
Adequate postoperative analgesia in children is a vital part of perioperative care. Regional block given preoperatively in combination with general anesthesia (GA) provides good preemptive analgesia. It is associated with perioperative hemodynamic stability, rapid and complete recovery and reduced analgesic requirement in the postoperative period.
CP repair is painful, necessitating high doses of intravenous (IV) opioids. Therefore, the risk of postoperative respiratory depression and airway obstruction is important, and continuous monitoring is required during the initial 24-h postoperative period. Cleft palate surgery is not only painful, but may also compromise the airway, particularly in children with craniofacial syndromes. Opiate analgesia has the potential to further compromise the airway, whereas bilateral maxillary nerve block can provide analgesia without the risk of respiratory depression in these vulnerable patients. Bilateral maxillary nerve block is performed using a suprazygomatic approach and is based on a computer tomography study.
The nerve supply to the hard and soft palate is from the greater and lesser palatine nerves passing through the sphenopalatine ganglion. The maxillary nerve (MN) provides sensory innervation of the anterior and posterior palate, the upper dental arch, the maxillary sinus, and the posterior nasal cavity. Maxillary nerve block (MNB) through the infrazygomatic route, used for the treatment of trigeminal neuralgia in adults, permits anesthesia of the entire palatine territory. However, this nerve block has led to complications such as orbital puncture, intracranial injection, maxillary artery puncture, or posterior pharyngeal wall injury.
Detailed Description
A prospective randomized controlled double blind study using a computer generated randomization scheme will be conducted in Assiut University Hospitals and will be carried out on 60 children undergoing primary cleft palate repair surgery. Combined general anesthesia and regional bilateral maxillary nerve block (MNB) will be used for anesthesia in these surgeries.
The study drugs (used in MNB) and randomization will be prepared by the second anesthetist. The MNB and observed parameters (intraoperative and postoperative) will be done by the first anesthetist.
Children will be randomly allocated into one of two groups of 30 patients each:
Group L: children will receive 0.15 ml/kg of 0.2% Levobupivacaine
Group B: children will receive 0.15 ml/kg of 0.2% Bupivacaine
Preoperative Assessment
The day prior to surgery, all children participating in this study will undergo pre-anesthetic checkup (preoperative fitness) including detailed history from the parents, thorough general, physical and systematic examinations. Weight and height of all children will be carefully recorded.
Anesthetic Technique
Premedication: All children will be premedicated with intramuscular midazolam 0.05 mg/kg 10-20 minutes before induction of general anesthesia.
Monitoring: Pulse Oxymetry (SaO2), Non-Invasive Mean Arterial Blood Pressure (MABP), ECG, End Tidal CO2 (EtCO2) and Non-Invasive Temperature probes will be applied to each patient.
After 3 minutes of 100% pre-oxygenation, general anesthesia will be induced by Sevoflurane inhalation 4-6% MAC via facemask then intravenous line will be secured and intravenous fluids (NaCl 0.9%) will be started at the calculated volume and rate. Fentanyl 1 µg/kg and Propofol 1.5 mg/kg will be given intravenously then intubation with oral RAE tube of the appropriate size will be inserted and secured. Assisted ventilation will be adjusted to maintain 30-35 mmHg EtCO2. Anesthesia will be maintained with 100% O2 and Sevoflurane 2-4% MAC. Broad spectrum antibiotic will be given to each child participated in the study.
Suprazygomatic MNB: Bilateral suprazygomatic MNB will be performed after complete aseptic preparation of the skin and before surgery in an anesthetized patient. Success of MNB will be assessed by the lack of sympathetic response to surgical stimulation.
Data Collection
Demographic data: including age, sex, weight and height.
Intraoperative data: heart rate (HR), mean arterial pressure (MAP), ECG, SaO2, EtCO2 and Sevoflurane MAC % will be measured every 15 minutes after MNB till the end of the surgery.
Postoperative data: HR, MAP, SaO2 and respiratory rate (RR) will be measured at the same times of pain assessment times.
Pain Severity: pain will be assessed by the second anesthetist blinded to the study drug used. Pain score will be evaluated on arrival to recovery room (T0), 1, 2, 4, 6, 8, 12 and 24 hours using the FLACC pain scale (Face, Legs, Activity, Cry and Consolability scale). If FLACC score ≥ 3, IV nalbuphine 0.1 mg/kg will be given for supplemental analgesia.
Time of the first analgesic requirement, total dose of nalbuphine consumption or any adverse effects (sedation, vomiting, respiratory depression, bleeding at the puncture site or any systemic toxicity related to the local anesthetic) will also be recorded.
Sedation score: will be evaluated by the 4 points (1-4) score. (Awake and alert -1, Sedated and responding to verbal command-2, Sedated and responding to mild stimulus-3, Sedated and responding to moderate to severe physical stimulus-4).
Blood glucose level will be measured before MNB, 15 minutes after block and 2 hours after end of surgery.
Statistical Analysis
All data will be collected and processed using SPSS (SPSS Inc., Chicago, Illinois, USA) version 20. All results will be expressed as mean ± SD, range, numbers and percentages. Categorical data will be compared using Chi-Square test. Non parametric data will be compared using the Mann-Whitney U test. Numerical data will be compared using the Independent Samples Student t-Test. P ˂ 0.05 will be considered significant.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Recovery After Cleft Palate Surgery
Keywords
Levobupivacaine, Bupivacaine, Nerve Block, Cleft Palate
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
60 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Group L
Arm Type
Active Comparator
Arm Description
Children will receive 0.15 ml/kg of 0.2% Levobupivacaine
Arm Title
Group B
Arm Type
Active Comparator
Arm Description
Children will receive 0.15 ml/kg of 0.2% Bupivacaine
Intervention Type
Drug
Intervention Name(s)
Levobupivacaine
Intervention Description
Children will receive 0.15 ml/kg of 0.2% Levobupivacaine through bilateral suprazygomatic MNB.
Intervention Type
Drug
Intervention Name(s)
Bupivacaine
Intervention Description
Children will receive 0.15 ml/kg of 0.2% Bupivacaine through bilateral suprazygomatic MNB.
Primary Outcome Measure Information:
Title
recovery after surgery
Description
sedation of the child in the recovery room will be monitored
Time Frame
2 hours
Secondary Outcome Measure Information:
Title
FLACC score
Description
Nalbuphine will be given when visual analogue score ≥ 3
Time Frame
24 hours
Title
Intraoperative and Postoperative Complications
Description
percentage of patients with any complications will be recorded
Time Frame
24 hours
10. Eligibility
Sex
All
Minimum Age & Unit of Time
1 Year
Maximum Age & Unit of Time
10 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age 1-10 years
Both sexes
ASA I or II
Primary cleft palate
Exclusion Criteria:
Any allergy to local anesthetics
Coagulation disorders
Local infection or injury at site of MNB
Concomitant rhinoplasty
Associated other congenital anomalies
History of upper or lower airway diseases
History of sleep apnea
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
HAMDY A YOUSSEF, MD
Organizational Affiliation
Assiut University
Official's Role
Study Chair
Facility Information:
Facility Name
Assiut university hospital
City
Assiut
ZIP/Postal Code
71515
Country
Egypt
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Learn more about this trial
Comparative Study Between Levobupivacaine and Bupivacaine for Nerve Block During Pediatric Primary Cleft Palate Surgery
We'll reach out to this number within 24 hrs